跳到正文
收录说明
收录范围
保留计量方法研究、相关统计基础,以及实质涉及计量方法的应用、教程、比较和综述。书评、刊务及明确无关内容不公开;身份或相关性证据不足的记录保留待核,补充可靠材料后可重新判断。
当前期刊来源见下方官网链接及期刊目录。综合经济学与金融期刊逐篇筛查计量方向,证据不足时暂不公开。正刊、在线优先论文和已核实接收稿合并展示;按标题、可靠摘要、目录及身份匹配的出版社 JEL 分类核验相关性;计量类 JEL 与摘要相互印证,无 JEL 不直接排除。历史回补以可取得的注册题录和目录为准,不等于覆盖全部纸本。
日期与排序
默认按最近发表排序:正刊使用刊期,待刊使用上线日期;缺少上线日期时,排序参考登记或首次收录时间,并在卡片注明。更多筛选可选择出版状态和日期口径;卷期依据出版社元数据,不因待刊时间较长而推定已编入正刊。仅有月份或年份时,日期区间相交也会纳入。

日期精度:到日 12 篇 · 到月 1 篇 · 到年 0 篇

分类与引用
领域和方法依据题名、摘要初步分类,可人工修正;分类不代表论文质量。引用数采用 OpenAlex 单条关联记录,不合计版本。
更新与 AI 解读
正常题录、可靠摘要与引用同步继续;日、周、月简报按核实的发表与修订日期汇总,历史补录保留在文献库。AI 解读依据可靠摘要或已核实原文片段,已有解读保留供阅读参考;缺少可靠材料的条目保持待解读,浏览页面不会触发生成。
13 篇论文
导出

Weight-Calibrated Estimation for Factor Models of High-Dimensional Time Series

高维时间序列因子模型的权重校准估计

The factor modeling for high-dimensional time series is powerful in discovering latent common components for dimension reduction and information extraction. Most available estimation methods can be divided into two categories: the covariance-based under asymptotically-identifiable assumption and the autocovariance-based with white idiosyncratic noise. This paper follows the autocovariance-based framework and develops a novel weight-calibrated method to improve the estimation…

AI 解读阅读原文 ↗BibTeX ↓

Estimating the number of significant components in high-dimensional principal component analysis

高维主成分分析中显著成分数量的估计

Abstract We consider the problem of estimating the number of significant components in high-dimensional principal component analysis. We propose a new penalized approach using the explained variance ratio and the rigidity of the nonspiked sample eigenvalues of sample covariance matrices of $ p $ variables. Compared with methods in the existing literature, the consistency of the proposed estimator holds, not only for independent data, but also for some times series data when…

AI 解读阅读原文 ↗BibTeX ↓

Network-Assisted High-Dimensional Factor Model Estimation

网络辅助的高维因子模型估计

This article takes advantage of group-level heterogeneity and network cohesion phenomenon to improve the estimation accuracy of approximate factor models. As large heterogeneous panels become available, a grouped pattern of unobserved heterogeneity in the panel data is highlighted. Clustering of factor loadings provides a solution to model group-level heterogeneity. Moreover, networks are frequently observed in economics and finance, which capture the interconnectivity…

AI 解读阅读原文 ↗BibTeX ↓

Identifying the Structure of High-Dimensional Time Series via Eigen-Analysis

通过特征值分析识别高维时间序列结构

Cross-sectional structures and temporal tendency are important features of high-dimensional time series. Based on eigen-analysis on sample covariance matrices, we propose a novel approach to identifying four popular structures of high-dimensional time series, which are grouped in terms of factor structures and stationarity. The proposed three-step method includes a ratio statistic of empirical eigenvalues;a projected Augmented Dickey-Fuller Test;a new unit-root test based on…

AI 解读阅读原文 ↗BibTeX ↓

Manipulating an Instrumental Variable in an Observational Study of Premature Babies: Design, Bounds, and Inference

早产儿观察研究中的工具变量强化:设计、界限与推断

Regionalization of intensive care for premature infants refers to a triage system that directs mothers to hospitals with varying capabilities based on the risks their babies face. Given the limited capacity of highly specialized hospitals, understanding the impact of delivering premature infants at these facilities on infant mortality could facilitate the design of a more efficient perinatal regionalization system. To address this, Baiocchi et al. proposed strengthening a…

AI 解读阅读原文 ↗BibTeX ↓

Generalizing the Intention-to-Treat Effect of an Active Control from Historical Placebo-Controlled Trials: A Case Study of the Efficacy of Daily Oral TDF/FTC in the HPTN 084 Study

从历史安慰剂对照试验推广活性对照的意向治疗效应:HPTN 084 案例

In many clinical settings, an active-controlled trial design (e.g., a non-inferiority or superiority design) is often used to compare an experimental medicine to an active control (e.g., an FDA-approved, standard therapy). One prominent example is a recent phase 3 efficacy trial, HIV Prevention Trials Network Study 084 (HPTN 084), comparing long-acting cabotegravir, a new HIV pre-exposure prophylaxis (PrEP) agent, to the FDA-approved daily oral tenofovir disoproxil fumarate…

AI 解读阅读原文 ↗BibTeX ↓

Factor Modeling for Clustering High-Dimensional Time Series

用于高维时间序列聚类的因子建模

We propose a new unsupervised learning method for clustering a large number of time series based on a latent factor structure.Each cluster is characterized by its own cluster-specific factors in addition to some common factors which impact on all the time series concerned.Our setting also offers the flexibility that some time series may not belong to any clusters.The consistency with explicit convergence rates is established for the estimation of the common factors, the…

AI 解读阅读原文 ↗BibTeX ↓

Estimating and improving dynamic treatment regimes with a time-varying instrumental variable

利用时变工具变量估计与改进动态治疗方案

Abstract Estimating dynamic treatment regimes (DTRs) from retrospective observational data is challenging as some degree of unmeasured confounding is often expected. In this work, we develop a framework of estimating properly defined ‘optimal’ DTRs with a time-varying instrumental variable (IV) when unmeasured covariates confound the treatment and outcome, rendering the potential outcome distributions only partially identified. We derive a novel Bellman equation under…

AI 解读阅读原文 ↗BibTeX ↓

Estimating Optimal Treatment Rules with an Instrumental Variable: A Partial Identification Learning Approach

利用工具变量估计最优治疗规则:部分识别学习方法

Abstract Individualized treatment rules (ITRs) are considered a promising recipe to deliver better policy interventions. One key ingredient in optimal ITR estimation problems is to estimate the average treatment effect conditional on a subject’s covariate information, which is often challenging in observational studies due to the universal concern of unmeasured confounding. Instrumental variables (IVs) are widely used tools to infer the treatment effect when there is…

AI 解读阅读原文 ↗BibTeX ↓

Selecting and Ranking Individualized Treatment Rules With Unmeasured Confounding

存在未测量混杂时个体化治疗规则的选择与排序

It is common to compare individualized treatment rules based on the value function, which is the expected potential outcome under the treatment rule. Although the value function is not point-identified when there is unmeasured confounding, it still defines a partial order among the treatment rules under Rosenbaum’s sensitivity analysis model. We first consider how to compare two treatment rules with unmeasured confounding in the single-decision setting and then use this…

AI 解读阅读原文 ↗BibTeX ↓

CLT for largest eigenvalues and unit root testing for high-dimensional nonstationary time series

高维非平稳时间序列最大特征值的中心极限定理与单位根检验

Let $\{Z_{ij}\}$ be independent and identically distributed (i.i.d.) random variables with $EZ_{ij}=0$, $E\vert Z_{ij}\vert^{2}=1$ and $E\vert Z_{ij}\vert^{4}<\infty$. Define linear processes $Y_{tj}=\sum_{k=0}^{\infty}b_{k}Z_{t-k,j}$ with $\sum_{i=0}^{\infty}\vert b_{i}\vert <\infty$. Consider a $p$-dimensional time series model of the form $\mathbf{x}_{t}=\boldsymbol{\Pi} \mathbf{x}_{t-1}+\Sigma^{1/2}\mathbf{y}_{t},\ 1\leq t\leq T$ with $\mathbf{y}_{t}=(Y_{t1},\ldots,Y_{tp})'$…

AI 解读阅读原文 ↗BibTeX ↓

The Tracy–Widom law for the largest eigenvalue of F type matrices

F 型矩阵最大特征值的 Tracy–Widom 分布律

Let ${\mathbf{A}}_{p}=\frac{{\mathbf{Y}}{\mathbf{Y}}^{*}}{m}$ and ${\mathbf{B}}_{p}=\frac{{\mathbf{X}}{\mathbf{X}}^{*}}{n}$ be two independent random matrices where ${\mathbf{X}}=(X_{ij})_{p\times n}$ and ${\mathbf{Y}}=(Y_{ij})_{p\times m}$ respectively consist of real (or complex) independent random variables with $\mathbb{E}X_{ij}=\mathbb{E}Y_{ij}=0$, $\mathbb{E}|X_{ij}|^{2}=\mathbb{E}|Y_{ij}|^{2}=1$. Denote by $\lambda_{1}$ the largest root of the determinantal equation $\det(\lambda{\mathbf{A}}_{p}-{\mathbf{B}}_{p})=0$…

AI 解读阅读原文 ↗BibTeX ↓

Joint Estimation of Treatment and Placebo Effects in Clinical Trials With Longitudinal Blinding Assessments

利用纵向盲法评估联合估计治疗效应与安慰剂效应

In some therapeutic areas, treatment evaluation is frequently complicated by a possible placebo effect (i.e., the psychobiological effect of a patient's knowledge or belief of being treated). When a substantial placebo effect is likely to exist, it is important to distinguish the treatment and placebo effects in quantifying the clinical benefit of a new treatment. These causal effects can be formally defined in a joint causal model that includes treatment (e.g., new versus…

AI 解读阅读原文 ↗BibTeX ↓